Jun 26, 2017 by Brian Orelli, PhDWhy ImmunoGen, Inc. Jumped Higher on MondayPositive early-stage data sends the biotech's shares up.
Jun 26, 2017 by Brian Orelli, PhDWhy Shares of Seattle Genetics, Inc. Got Whacked TodaySometimes good news isn't good enough.
Jun 21, 2017 by Brian Orelli, PhDWhy ImmunoGen, Inc. Jumped Higher for the Second Day in a RowThe biotech is on fire, but the reason is a mystery.
Jun 9, 2017 by Brian Orelli, PhD6 Reasons Why Prescription Drug Prices Are Extremely ExpensiveThere are myriad reasons going to the drugstore hurts the wallet.
Jun 8, 2017 by Brian Orelli, PhDWhy Valeant Pharmaceuticals Intl. Inc. Jumped Higher TodayThe pharmaceutical company continues to sell off assets to pay down debt.
Jun 8, 2017 by Brian Orelli, PhDCantel Medical Corp. Gives the Bottom Line a BoostIt's hard to complain about the medical supply company growing its earnings faster than its revenue.
Jun 8, 2017 by Brian Orelli, PhDThe Best Hep C Drug Stock to Buy in 2017 Each drugmaker has unique opportunities, but only one can come out on top.
Jun 7, 2017 by Brian Orelli, PhDWhy bluebird bio Inc. Flew Higher Again TodayThe biotech's post-ASCO run continues.
Jun 6, 2017 by Brian Orelli, PhDWhy bluebird bio Inc Flew Higher TodaySolid early-stage data for its CAR-T treatment bb2121 has investors looking up.
Jun 2, 2017 by Brian Orelli, PhDWhy TG Therapeutics Inc Jumped Higher TodayInvestors are looking forward to the biotech's presentation at the American Society of Clinical Oncology (ASCO) meeting.
Jun 2, 2017 by Brian Orelli, PhDWhy XBiotech Inc Jumped Higher TodayInvestors are focused on the wrong data.
May 31, 2017 by Brian Orelli, PhDHow Regeneron Pharmaceuticals, Inc. Makes Most of Its MoneyOne drug dominates, but diversification is coming.
May 25, 2017 by Brian Orelli, PhDI Still Can't Believe Juno Therapeutics Spent $46.4 Million on This Failed DrugA costly learning exercise.
May 24, 2017 by Brian Orelli, PhDWhy Puma Biotechnology Inc Jumped Higher TodayA positive FDA advisory committee meeting makes approval of Puma's breast-cancer drug likely.
May 22, 2017 by Brian Orelli, PhDWhy Puma Biotechnology Inc Jumped Higher TodayDocuments from the FDA suggest the agency is open to the possibility of approving neratinib.
May 18, 2017 by Brian Orelli, PhDWhy ImmunoGen, Inc. Jumped Higher TodayData to be presented at ASCO looks strong.
May 15, 2017 by Brian Orelli, PhDGenomic Health, Inc. Waits for ReimbursementMeanwhile, the genetic-test maker is increasing margins on its way to profitability.
May 15, 2017 by Brian Orelli, PhDWhy ImmunoGen, Inc. Stock Is Flying High TodayAmerican Society of Clinical Oncology meeting abstracts will be released on Wednesday evening.
